. Author manuscript; available in PMC: 2016 Mar 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):281–288. doi: 10.1097/QAI.0000000000000458

Table 2.

Difference in Neurocognitive Function and Metabolic Syndrome Components by Gender and Obesity

Variables from N=152 Age^*	WOMEN (WC<88) N=7 50 (39, 55)	WOMEN (WC>88) N=16 49 (41, 55)	P value^**	Men (WC <102) N=94 50 (44, 54)	MEN (WC≥102) N=35 49 (45, 57)	P value	P value Obese W vs M
Global Deficit Score	0.07 (0.00, 0.20)^*	0.23 (0.00, 0.54)	0.21 (0.05)^†	0.20 (0.07, 0.47)	0.47 (0.13, 1.07)	0.01	0.08
No. with NCI^†† (%)	0	5 (31)	0.27	21(22)	17(49)	0.004	0.25
Systolic pressure mm Hg	119 (116, 123)	106 (100, 120)	0.62	126 (116, 135)	130 (120, 138)	0.39	0.0008
Total Cholesterol, mg/dL	164 (131, 200)	204 (192, 229)	0.03	180 (157, 204)	183 (163, 209)	0.53	0.04
LDL-Cholesterol, mg/dL	85 (50, 114)	118 (101, 139)	0.03	98 (78, 120)	104 (82, 129)	0.38	0.10
HDL-cholesterol, mg/dL	55 (47, 77)	58 (54, 66)	0.44	47 (37, 59)	38 (29, 50)	0.006	<0.0001
Triglycerides, mg/dL	131 (60, 171)	113 (88, 147)	0.66	143 (89, 210)	201 (131, 308)	0.01	0.0007
HOMA-IR	1.19 (1.04, 1.27)	2.00 (1.37, 3.24)	0.05	1.92 (1.04, 3.81)	4.16 (2.70, 6.81)	0.0003	0.01
Plasma adiponectin, ng/ml × 10³	5.3 (3.9, 9.4)	4.5 (3.5, 6.8)	0.49	4.3 (2.4, 6.0)	3.2 (2.5, 3.9)	0.04	0.009

Medians (first and third quartiles)

^**

Wilcoxon nonparametric p-values were used for all other comparisons

^†

0.05 by T test

^††

neurocognitive impairment